# Sinovac Biotech Ltd (SVA)

Source page: https://stoqly.net/companies/sva

- **Ticker:** SVA (Nasdaq)
- **Sector:** Health Care / Pharmaceutical Preparations
- **SEC CIK:** 0001084201
- **Latest annual report:** 20-F filed 2026-06-05 (https://www.sec.gov/Archives/edgar/data/1084201/000119312526258534/sva-20251231.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $6.47 on 2025-03-21
- **Market cap:** $465M
- **EPS, trailing 12 months:** −$0.83
- **Revenue (FY2025):** $386M
- **Revenue growth:** +6.8%
- **Revenue growth, 5-year CAGR:** −5.4%
- **Gross margin:** 67.9%
- **Operating margin:** −127.0%
- **Net margin:** −51.5%
- **Free cash flow:** −$561M
- **Free cash flow margin:** −145.4%
- **Return on equity:** −3.1%
- **Net debt:** −$5.5B
- **Change in share count:** 0.0%
- **Piotroski F-score:** 3/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/sva/figures.csv

| US$ millions | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | 72 | 174 | 230 | 246 | 511 | 19,365 | 1,473 | 470 | 361 | 386 |
| Operating income | 1 | 45 | 45 | 69 | 216 | 17,618 | -509 | -714 | -506 | -490 |
| Net income | -1 | 26 | 22 | 45 | 110 | 8,122 | 14 | -13 | 41 | -199 |
| Diluted EPS (US$) | -0.01 | 0.45 | 0.34 | 0.41 | 0.97 | 113.44 | 0.20 | -0.19 | 1.27 | -0.83 |
| Operating cash flow | -14 | 60 | 8 | 39 | 479 | 15,322 | -798 | 139 | -57 | -512 |
| Free cash flow | -27 | 48 | 2 | 28 | 352 | 14,728 | -1,112 | -18 | -153 | -561 |
| Cash | 62 | 114 | 177 | 203 | 1,176 | 13,415 | 10,532 | 11,019 | 9,949 | 5,971 |
| Debt and leases | 72 | 51 | 11 | 6 | 35 | 16 | 12 | 254 | 376 | 495 |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.